TRexBio Secures $84 Million in Series B Funding for Immunology Advances

TRexBio, a biotech firm concentrating on human tissue immune biology, has successfully closed an $84 million Series B funding round, primarily led by Delos Capital with participation from investors such as Avego BioScience Capital, Agent Capital, and a number of existing supporters including Eli Lilly, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Alexandria Venture Investments, and Polaris Partners. This financing aims mainly to drive the development of TRB-061, a novel TNFR2 agonist designed to treat immune-mediated diseases, towards early clinical proof of concept. The planned Phase 1 clinical trial for TRB-061 is set for the first half of 2025. Furthermore, this investment will facilitate the expansion of TRexBio's therapeutic pipeline, supporting the growth of candidates like TRB-071. Distinguished figures such as Dr. Eric Huang from Delos, Joel S. Marcus from Alexandria Venture Investments, and Dr. Eric Pham from Avego have joined the TRexBio Board, which signifies strong backing from the financial and scientific communities. The firm, founded by SV Health Investors in 2018 and based in South San Francisco, continues to build on alliances with partners including Eli Lilly and Johnson & Johnson to navigate the innovative path of targeting regulatory T cells for autoimmune and inflammatory diseases treatment.